Oxford Biomedica PLC

Report Publication Announcement • Aug 6, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2090V

Oxford Biomedica PLC

06 August 2015

Oxford BioMedica: Notice of Interim Results 

Results date: 27 August 2015

Oxford, UK - 6 August 2015: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Group") a leading gene and cell therapy group, will be announcing its interim results for the six month months ended 30 June 2014 on Thursday 27 August 2015 at 7am BST.

An analyst briefing will be held at 9:30am BST on 27 August 2015 at the offices of Consilium Strategic Communications: 41 Lothbury, EC2R 7HG. An audio replay will be made available shortly after the presentation on the Group's website: www.oxfordbiomedica.co.uk.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: +44 (0)1865 783 000
Media Enquiries: Mary-Jane Elliott/ Matthew Neal/ Chris Welsh/ Laura Thornton Consilium Strategic Communications	Tel: +44 (0)20 3709 5700

Notes to editors

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk .

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORLELFBEVFZBBV